| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
PYC Therapeutics Ltd
PYC Therapeutics Ltd
ASX:PYC
PYC Therapeutics Ltd
Total Assets
PYC Therapeutics Ltd
Total Assets Peer Comparison
IMM
MSB
CSL
CUV
TLX
Competitive Total Assets Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Assets
AU$39.8m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
29%
|
CAGR 10-Years
18%
|
|
|
Immutep Ltd
ASX:IMM
|
Total Assets
AU$123.8m
|
CAGR 3-Years
17%
|
CAGR 5-Years
21%
|
CAGR 10-Years
14%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Assets
$670.3m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Total Assets
$37.3B
|
CAGR 3-Years
28%
|
CAGR 5-Years
26%
|
CAGR 10-Years
20%
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Total Assets
AU$211.7m
|
CAGR 3-Years
34%
|
CAGR 5-Years
36%
|
CAGR 10-Years
32%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Assets
AU$398.3m
|
CAGR 3-Years
36%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
See Also
What is PYC Therapeutics Ltd's Total Assets?
Total Assets
39.8m
AUD
Based on the financial report for Dec 31, 2023, PYC Therapeutics Ltd's Total Assets amounts to 39.8m AUD.
What is PYC Therapeutics Ltd's Total Assets growth rate?
Total Assets CAGR 10Y
18%
Over the last year, the Total Assets growth was 26%. The average annual Total Assets growth rates for PYC Therapeutics Ltd have been -14% over the past three years , 29% over the past five years , and 18% over the past ten years .
You don't have any saved screeners yet
